This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Flather M et al. (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-inhibitor Myocardial Infarction Collaborative Group. Lancet 355: 1575–1581
Pfeffer M et al. (2003) Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893–1906
Pitt B et al. for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309–1321
Tengs T et al. (1995) Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 15: 369–390
Acknowledgements
The synopsis was written by Hannah Camm, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Dickstein, K. Is eplerenone a cost-effective therapy for heart failure patients after myocardial infarction?. Nat Rev Cardiol 2, 440–441 (2005). https://doi.org/10.1038/ncpcardio0296
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio0296